Screener
Arbutus Biopharma Corporation ABUS Restructuring Charges
Restructuring Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 4,120 | 8,959 |
| General and administrative | 5,889 | 5,832 |
| Change in fair value of contingent consideration | 209 | 299 |
| Restructuring costs | — | 12,373 |
| Total operating expenses | 10,218 | 27,463 |
| Income (loss) from operations | 168,908 | (25,699) |
| Other income | ||
| Interest income | 815 | 1,197 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's restructuring charges?
- Arbutus Biopharma Corporation (ABUS) reported restructuring charges of $0 in Q1 2026.
- How has Arbutus Biopharma Corporation's restructuring charges changed year-over-year?
- Arbutus Biopharma Corporation's restructuring charges decreased by 100.0% year-over-year, from $12.37M to $0.
- What does restructuring charges mean?
- One-time costs from reorganizing operations, including employee severance, facility closure costs, contract termination fees, and asset relocation expenses.
Ask your AI about Arbutus Biopharma Corporation's restructuring charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude